<SEC-DOCUMENT>0001193125-24-219153.txt : 20240916
<SEC-HEADER>0001193125-24-219153.hdr.sgml : 20240916
<ACCEPTANCE-DATETIME>20240916060530
ACCESSION NUMBER:		0001193125-24-219153
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240914
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240916
DATE AS OF CHANGE:		20240916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvalent, Inc.
		CENTRAL INDEX KEY:			0001861560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40671
		FILM NUMBER:		241299244

	BUSINESS ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		508-446-2272

	MAIL ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d862522d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nuvl="http://www.nuvalent.com/20240914" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-283">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-14_to_2024-09-14">0001861560</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="nuvl-20240914.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-14_to_2024-09-14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-14</xbrli:startDate> <xbrli:endDate>2024-09-14</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-294">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt:datemonthdayyearen" id="ixv-295">September&#160;14, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-296">NUVALENT, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:stateprovnameen" id="ixv-297">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-298">001-40671</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-299">81-5112298</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-300">Nuvalent, Inc.</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-301">One Broadway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-302">14th Floor</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-303">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:stateprovnameen" id="ixv-304">Massachusetts</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-305">02142</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, including zip code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-306">(857)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-307">357-7000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:boolballotbox" id="ixv-308">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:boolballotbox" id="ixv-309">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:boolballotbox" id="ixv-310">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:boolballotbox" id="ixv-311">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trade<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-312">Class&#160;A Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-313">NUVL</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:exchnameen" id="ixv-314">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-09-14_to_2024-09-14" format="ixt-sec:boolballotbox" id="ixv-315">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;14, 2024, Nuvalent, Inc. (the &#8220;Company&#8221;) issued a press release announcing updated data from the fully enrolled Phase 1 dose-escalation portions of its ongoing <span style="white-space:nowrap">ARROS-1</span> Phase 1/2 clinical trial of zidesamtinib, a novel ROS1-selective inhibitor, and <span style="white-space:nowrap">ALKOVE-1</span> Phase 1/2 clinical trial of <span style="white-space:nowrap">NVL-655,</span> a novel <span style="white-space:nowrap">ALK-selective</span> inhibitor, which updated data was presented during two oral presentations at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. In addition, the press release announced progress and provided updates on the development strategy and timelines for the Company&#8217;s parallel-lead programs zidesamtinib and <span style="white-space:nowrap">NVL-655,</span> including the Company&#8217;s design and timing of its planned ALKAZAR Phase 3 randomized, controlled trial of <span style="white-space:nowrap">NVL-655</span> for tyrosine kinase <span style="white-space:nowrap">inhibitor-na&#239;ve</span> patients with advanced <span style="white-space:nowrap">ALK-positive</span> <span style="white-space:nowrap">non-small</span> cell lung cancer. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d862522dex991.htm">Press Release issued by Nuvalent, Inc. on September&#160;14, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 hereto, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the Company&#8217;s strategy, business plans, and focus; the clinical development programs for zidesamtinib and <span style="white-space:nowrap">NVL-655;</span> the expected timing of reporting data readouts from the Company&#8217;s clinical trials of zidesamtinib and <span style="white-space:nowrap">NVL-655;</span> the design and timing of the ALKAZAR trial, including alignment with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) regarding the design of the trial; the potential clinical effects of zidesamtinib and <span style="white-space:nowrap">NVL-655;</span> the potential of the Company&#8217;s pipeline programs, including zidesamtinib and <span style="white-space:nowrap">NVL-655;</span> the implications of data readouts and presentations; the Company&#8217;s research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. Any forward-looking statements in this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 hereto, are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 hereto and without limitation: risks that the Company may not fully enroll the <span style="white-space:nowrap">ARROS-1,</span> <span style="white-space:nowrap">ALKOVE-1</span> or ALKAZAR trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies or clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from the Company&#8217;s clinical trials may not be sufficient to support registration and that the Company may be required to conduct one or more additional studies or trials prior to seeking registration of its product candidates; risks that the Company may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA, European Medicines Agency or other foreign regulators may not approve the Company&#8217;s potential products on the timelines the Company expects, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that the Company may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of the Company&#8217;s clinical trials, strategy, and future operations, including the <span style="white-space:nowrap">ARROS-1,</span> <span style="white-space:nowrap">ALKOVE-1</span> and ALKAZAR trials; the timing and outcome </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company&#8217;s planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting the Company&#8217;s intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarterly period ended June&#160;30, 2024, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Nuvalent, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September&#160;16, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Deborah Miller</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Deborah Miller, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Legal Officer and Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d862522dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Nuvalent.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and <FONT
STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC and Accelerated Development Timelines </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Updated Phase 1 dose-escalation data
from <FONT STYLE="white-space:nowrap">ARROS-1</FONT> and <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> clinical trials continue to support potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
profiles for zidesamtinib and <FONT STYLE="white-space:nowrap">NVL-655</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Rapid enrollment in Phase 2 portions of the <FONT
STYLE="white-space:nowrap">ARROS-1</FONT> and <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Initiation of ALKAZAR Phase 3 randomized, controlled trial of <FONT STYLE="white-space:nowrap">NVL-655</FONT> for <FONT
STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> patients with advanced <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC anticipated in the first half of 2025 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company to host a conference call today at 8:30 a.m. ET/2:30 p.m. CEST </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CAMBRIDGE, Mass. &#151; Sept. 14, 2024</B> &#151;&nbsp;<U>Nuvalent, Inc</U>. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on
creating<I>&nbsp;precisely</I>&nbsp;targeted therapies for clinically proven kinase targets in cancer, today highlighted the presentation of updated data from the fully enrolled Phase 1 dose-escalation portions of the ongoing <FONT
STYLE="white-space:nowrap">ARROS-1</FONT> Phase 1/2 clinical trial of zidesamtinib, a novel ROS1-selective inhibitor, and <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">NVL-655,</FONT> a
novel <FONT STYLE="white-space:nowrap">ALK-selective</FONT> inhibitor, during two oral presentations at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the company announced progress and provided updates on the development strategy and timelines for its parallel-lead programs zidesamtinib and <FONT
STYLE="white-space:nowrap">NVL-655,</FONT> including its development strategy for tyrosine kinase inhibitor <FONT STYLE="white-space:nowrap">(TKI)-na&iuml;ve</FONT> <FONT STYLE="white-space:nowrap">ALK-positive</FONT>
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2 portion of the <FONT STYLE="white-space:nowrap">ARROS-1</FONT> trial of zidesamtinib for <FONT
STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> and TKI <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients with advanced ROS1-positive NSCLC and other solid tumors:</B> Between September 2023 and September&nbsp;1, 2024, 227 patients were
enrolled in the ongoing <FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-cohort Phase 2 portion of the <FONT STYLE="white-space:nowrap">ARROS-1</FONT> trial, which is designed with registrational intent. The company expects to report
pivotal data from this trial in 2025. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2 portion of the <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> trial of <FONT
STYLE="white-space:nowrap">NVL-655</FONT> for <FONT STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> and TKI <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients with advanced <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC and
other solid tumors:</B> Between February 2024 and September&nbsp;1, 2024, 229 patients were enrolled in the ongoing <FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-cohort Phase 2 portion of the
<FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> trial, which is designed with registrational intent for TKI <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients. The company also expects to report pivotal data from this trial in 2025.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ALKAZAR Phase 3 </B><B>randomized, controlled</B><B> trial of
<FONT STYLE="white-space:nowrap">NVL-655</FONT></B><B> for <FONT STYLE="white-space:nowrap">TKI-na</FONT></B><B>&iuml;</B><B>ve patients with advanced <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC:</B> The Phase 3 ALKAZAR trial will be
a global, randomized, controlled trial designed to evaluate <FONT STYLE="white-space:nowrap">NVL-655</FONT> versus the current standard of care for the treatment of patients with <FONT STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> <FONT
STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC. Patients will be randomized 1:1 to receive <FONT STYLE="white-space:nowrap">NVL-655</FONT> monotherapy or ALECENSA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (alectinib)
monotherapy, reflecting input from collaborating physician-scientists and alignment with the U.S. Food and Drug Administration (FDA). The company plans to initiate the ALKAZAR study in the first half of 2025. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 1 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The Phase 1 portions of our <FONT STYLE="white-space:nowrap">ARROS-1</FONT> and <FONT
STYLE="white-space:nowrap">ALKOVE-1</FONT> studies have established preliminary clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for zidesamtinib and
<FONT STYLE="white-space:nowrap">NVL-655</FONT> as selective, brain-penetrant, <FONT STYLE="white-space:nowrap">TRK-sparing</FONT> TKIs that have the potential to move up the treatment paradigm, as demonstrated by the preliminary safety profile
indicating favorable tolerability, and the durability of responses observed across patient subsets presented today at ESMO,&#148; said&nbsp;Christopher Turner, M.D., Chief Medical Officer at Nuvalent.&nbsp;&#147;We believe zidesamtinib and <FONT
STYLE="white-space:nowrap">NVL-655</FONT> have the potential to not only address clear medical needs in the third line where no approved therapies have demonstrated clinical benefit, but also provide differentiated options in the second line
including for patients who have experienced disease progression due to CNS metastases or resistance mutations, and ultimately deliver deep, durable responses in the front line.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are grateful for the strong investigator enthusiasm for our programs, exemplified by the accelerated Phase 2 enrollment in our <FONT
STYLE="white-space:nowrap">ARROS-1</FONT> and <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> trials. We now anticipate reporting pivotal datasets from both Phase 2 trials in 2025,&#148; said Darlene Noci, A.L.M., Chief Development Officer at
Nuvalent. &#147;With the announcement of our planned ALKAZAR randomized, controlled Phase 3 study, we are thrilled to also establish a potential registration path for <FONT STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> patients with advanced <FONT
STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC. Through our multi-pronged strategies, our goal is to bring potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies that can move up the
treatment paradigm to patients as efficiently as possible. We look forward to initiating the ALKAZAR study in the first half of 2025.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ALKAZAR
trial is designed to enroll approximately 450 patients with <FONT STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC. The primary endpoint is progression free survival (PFS) based on Blinded
Independent Central Review (BICR). Secondary endpoints include PFS based on investigator&#146;s assessment, and BICR assessment of objective response rate (ORR), intracranial objective response rate <FONT STYLE="white-space:nowrap">(IC-ORR),</FONT>
overall survival (OS), and safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;At the outset of this year, we announced our OnTarget 2026 operating plan delineating our path towards a
potential first approval in 2026 from our pipeline of novel kinase inhibitors. With today&#146;s updates, we have successfully achieved all of the supporting milestones<B> </B>laid out for 2024 and believe we are now on track to share pivotal
datasets from both of our parallel-lead programs in 2025, a testament to the tireless dedication of our team,&#148; said James Porter, Ph.D., Chief Executive Officer at Nuvalent.<B> </B>&#147;I am incredibly proud of what we have accomplished thus
far and am optimistic about the road ahead. With the foundation of encouraging Phase 1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data, strong enrollment momentum in our global Phase 2 trials,
alignment with the FDA on the design of our Phase 3 ALKAZAR study, and the dedication of our proven team, we are confident in our ability to continue advancing our programs towards our goal of delivering them as quickly as possible to the patients
that need them.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">ARROS-1</FONT> Phase 1 Update at ESMO 2024 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From January 2022 to August 2023, the Phase 1 portion of <FONT STYLE="white-space:nowrap">ARROS-1</FONT> enrolled 104 patients (99 NSCLC, 5 other solid
tumors). Patients received zidesamtinib orally at dose levels ranging from 25 to 150 mg once daily (QD), and 100 mg QD was selected as the recommended Phase 2 dose (RP2D). No clinically significant exposure-response relationships for safety and
efficacy were observed and data are reported across all doses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 2 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patient population was heavily <FONT STYLE="white-space:nowrap">pre-treated,</FONT> with a median of 3
prior lines of therapy (range 1 &#150; 11). 69% (72/104) of patients had &#8805;2 prior ROS1 TKIs, and 66% (69/104) had prior chemotherapy. Notably, 55% (57/104) of patients received prior lorlatinib and 21% (22/104) received prior repotrectinib,
highlighting the differentiated nature of this population from prior trials of other ROS1 inhibitors. 52% (54/104) had history of CNS metastases, including cases of disease progression following treatment with the brain-penetrant TKIs lorlatinib
and/or repotrectinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the <FONT STYLE="white-space:nowrap">cut-off</FONT> date of July&nbsp;1, 2024, 71
<FONT STYLE="white-space:nowrap">pre-treated</FONT> patients with ROS1-positive NSCLC were response-evaluable. The median <FONT STYLE="white-space:nowrap">follow-up</FONT> for the <FONT STYLE="white-space:nowrap">all-treated</FONT> population was
12.1 months (range, 0.8 &#150; 29.4). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with zidesamtinib resulted in durable clinical responses (ORR by RECIST 1.1) across key subgroups of
response-evaluable patients. As of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>ROS1-positive NSCLC response-evaluable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Zidesamtinib, All Doses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ORR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>mDOR<BR>(months)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DOR </B>&#8805;<B></B><B></B><br><B>6&nbsp;months*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DOR </B>&#8805;<B></B><B></B><br><B>12&nbsp;months*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Any Prior Therapies</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(1 &#150; 4 prior ROS1 TKIs&#8201;&plusmn; chemotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">44%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(31/71,&nbsp;2&nbsp;CRs)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Repotrectinib-naive</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">51%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(27/53)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>&#8805;<B></B><B>2 prior ROS1 TKIs**</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(&#8805; 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Line; &plusmn; chemotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">41%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(21/51)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prior crizotinib only</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Line; &plusmn; chemotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">73%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(8/11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%***&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NR = not reached </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Analyses of DOR based on Kaplan-Meier estimates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zidesamtinib has received FDA breakthrough therapy designation for the treatment of patients with ROS1-positive
metastatic NSCLC who have been previously treated with 2 or more ROS1 TKIs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No disease progression among responders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the subset of patients with confirmed ROS1 G2032R resistance mutation, the ORR was 72% (13/18) for repotrectinib-na&iuml;ve patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IC-ORR</FONT> was 50% (4/8) in intracranial response-evaluable patients with measurable CNS lesions, of which 7/8 patients
had been previously treated with the brain-penetrant TKIs lorlatinib and/or repotrectinib. The mIC-DOR was not reached, with no CNS progression observed among confirmed CNS responders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zidesamtinib was well-tolerated with a preliminary safety profile that was favorable and consistent with its ROS1-selective, TRK sparing design. Among the 104
treated patients at all doses, the most frequent treatment-related adverse events (TRAEs) were oedema peripheral (19%), ALT increase, AST increase, and weight increase (each 11%). Among these most frequent TRAEs, there was a single grade 3 event of
weight increase. No discontinuation due to TRAEs occurred. Dose reductions due to TRAEs occurred in 8% of patients. A maximum tolerated dose was not identified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 3 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company believes these preliminary data demonstrate the potential for zidesamtinib to address a medical
need for the third-line treatment of ROS1-positive NSCLC where no approved therapies have demonstrated clinical benefit, and to provide a differentiated option in the second line where there also remains a medical need. Additionally, the company
believes that these data in heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients could have the potential to translate to deep, durable responses in the front-line setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further investigation of zidesamtinib for both <FONT STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> and TKI pretreated patients with ROS1-positive NSCLC is
underway in the Phase 2 portion of the <FONT STYLE="white-space:nowrap">ARROS-1</FONT> clinical trial, designed with registrational intent. The company expects to report pivotal data in 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> Phase 1 Update at ESMO 2024 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From June 2022 to February 2024, the Phase 1 portion of <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> enrolled 133 patients (131 NSCLC, 2 other solid
tumors). Patients received <FONT STYLE="white-space:nowrap">NVL-655</FONT> orally at dose levels ranging from 15 to 200 mg QD, and 150 mg QD was selected as the RP2D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patient population was heavily <FONT STYLE="white-space:nowrap">pre-treated,</FONT> with a median of 3 prior lines of therapy (range 1 &#150; 9). 46%
(61/133) of patients had &#8805;3 prior ALK TKIs, and 56% (74/133) had prior chemotherapy. Notably, 84% (111/133) of patients received prior lorlatinib and 51% (68/133) had any secondary ALK resistance mutation including 26% (34/133) with compound
(&#8805;2)&nbsp;ALK mutations, highlighting the differentiated nature of this population from prior trials of investigational ALK inhibitors. 56% (75/133) had history of CNS metastases, including cases of disease progression following treatment with
the brain-penetrant TKI lorlatinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the <FONT STYLE="white-space:nowrap">cut-off</FONT> date of June&nbsp;15, 2024, 103 heavily <FONT
STYLE="white-space:nowrap">pre-treated</FONT> patients with <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC treated across all doses were response-evaluable, of whom 39 were treated at the RP2D. The median
<FONT STYLE="white-space:nowrap">follow-up</FONT> for the <FONT STYLE="white-space:nowrap">all-treated</FONT> population was 8.0 months (range 0.2, 22.5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with <FONT STYLE="white-space:nowrap">NVL-655</FONT> resulted in durable clinical responses (ORR by RECIST 1.1) across key subgroups of
response-evaluable patients treated at the RP2D and across all dose levels. As of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 4 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><FONT STYLE="white-space:nowrap">ALK-positive</FONT>
NSCLC response-evaluable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">NVL-655</FONT> at RP2D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">NVL-655,</FONT> All Doses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ORR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>mDOR<BR>(months)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DOR </B>&#8805;<B></B><B></B><br><B>6&nbsp;months*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ORR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>mDOR<BR>(months)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DOR </B>&#8805;<B></B><B></B><br><B>6&nbsp;months*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Any Prior Therapies</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(1 &#150; 5 prior ALK TKIs &plusmn; chemotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">38%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(15/39)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">38%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(39/103)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lorlatinib <FONT STYLE="white-space:nowrap">pre-treated</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(&#8805; 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Line**; &plusmn; chemotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">35%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(11/31)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">35%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(30/85)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>With compound ALK resistance mutations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">64%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(7/11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">54%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(15/28)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lorlatinib-na&iuml;ve</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(&#8805; 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Line; &plusmn; chemotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">57%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(4/7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">53%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(9/17)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>With ALK resistance mutation(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">80%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(4/5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">88%<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(7/8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NR</TD>
<TD NOWRAP VALIGN="bottom">***&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%***&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NR = not reached </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Analyses of DOR based on Kaplan-Meier estimates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">NVL-655</FONT> has received FDA breakthrough therapy designation for the
treatment of patients with locally advanced or metastatic <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC who have been previously treated with 2 or more ALK TKIs </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No disease progression among responders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CNS responses were observed in patients with either measurable or unmeasurable CNS lesions across all doses, including complete intracranial responses in
patients who previously received the brain-penetrant TKI lorlatinib. No CNS progression was observed among all confirmed CNS responders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">NVL-655</FONT> was well-tolerated with a preliminary safety profile that was favorable and consistent with its <FONT STYLE="white-space:nowrap">ALK-selective,</FONT> TRK sparing design. Among the 133 patients treated at
all doses, the most frequent TRAEs were ALT increase (34%), AST increase (30%), constipation (16%), dysgeusia (13%), and nausea (12%). Among these most frequent TRAEs, 13% of patients experienced grade 3 ALT increase, one patient experienced grade 4
ALT increase, and 9% of patients experienced grade 3 AST increase. Transaminase elevations were generally transient and reversible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Discontinuations due
to TRAEs occurred in 2% of patients and dose-reductions occurred in 15% of patients. A maximum tolerated dose was not identified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company believes
these preliminary data demonstrate the potential for <FONT STYLE="white-space:nowrap">NVL-655</FONT> to address a medical need for the third-line treatment of <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC where no approved therapies
have demonstrated clinical benefit, and to provide a differentiated option in the second line. The ongoing Phase 2 portion of the <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> clinical trial is designed with registrational intent for TKI <FONT
STYLE="white-space:nowrap">pre-treated</FONT> patients with <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC, and the company expects to report pivotal data in 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 5 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the company believes that these data in heavily
<FONT STYLE="white-space:nowrap">pre-treated</FONT> patients could have the potential to translate to deep, durable responses in the front-line setting. The company plans to initiate the Phase 3 randomized, controlled, ALKAZAR study with
registrational intent for <FONT STYLE="white-space:nowrap">TKI-na&iuml;ve</FONT> patients in the first half of 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Conference Call Information
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following oral presentations at the ESMO Congress 2024 in Barcelona, Spain, management will host a live webcast and conference call on Saturday,
September&nbsp;14, 2024 at 8:30 a.m. ET/2:30 p.m. CEST. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To access the call, register online <U>here</U> for the live webcast or dial +1 (800) <FONT
STYLE="white-space:nowrap">836-8184</FONT> (domestic) or +1 (646) <FONT STYLE="white-space:nowrap">357-8785</FONT> (international) at least 10 minutes prior to the start time and ask to be joined to the Nuvalent call. Accompanying slides and a live
video webcast will be available in the Investors section of the Nuvalent website at&nbsp;<U>https://investors.nuvalent.com/events</U>. A replay and accompanying slides will be archived on the Nuvalent website for 30 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zidesamtinib and the <FONT STYLE="white-space:nowrap">ARROS-1</FONT> Phase 1/2 Clinical Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1
inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for
central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential
to avoid <FONT STYLE="white-space:nowrap">TRK-related</FONT> CNS adverse events seen with dual TRK/ROS1 inhibitors and to drive deep, durable responses for patients across all lines of therapy. Zidesamtinib has received breakthrough therapy
designation for the treatment of patients with ROS1-positive metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) who have been previously treated with 2 or more ROS1 tyrosine kinase inhibitors and orphan drug
designation for ROS1-positive NSCLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zidesamtinib is currently being investigated in the <FONT STYLE="white-space:nowrap">ARROS-1</FONT> trial
(<U>NCT05118789</U>), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1/2 clinical trial for patients with advanced ROS1-positive NSCLC and other solid tumors. The completed Phase 1 portion
enrolled ROS1-positive NSCLC patients who previously received at least one ROS1 TKI, or patients with other ROS1-positive solid tumors who had been previously treated. The Phase 1 portion of the trial was designed to evaluate the overall safety and
tolerability of <FONT STYLE="white-space:nowrap">NVL-520,</FONT> with additional objectives including determination of the recommended Phase 2 dose (RP2D), characterization of the pharmacokinetic profile, and evaluation of preliminary anti-tumor
activity. The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI na&iuml;ve and TKI <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients with ROS1-positive NSCLC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">NVL-655</FONT> and the <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> Phase 1/2 Clinical Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NVL-655</FONT> is a novel brain-penetrant <FONT STYLE="white-space:nowrap">ALK-selective</FONT> inhibitor created with the aim
to overcome limitations observed with currently available ALK inhibitors. <FONT STYLE="white-space:nowrap">NVL-655</FONT> is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors,
including tumors with single or compound treatment-emergent ALK mutations such as G1202R. In addition, <FONT STYLE="white-space:nowrap">NVL-655</FONT> is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 6 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor
kinase (TRK) family. Together, these characteristics have the potential to avoid <FONT STYLE="white-space:nowrap">TRK-related</FONT> CNS adverse events seen with dual TRK/ALK inhibitors and to drive deep, durable responses for patients across all
lines of therapy. <FONT STYLE="white-space:nowrap">NVL-655</FONT> has received breakthrough therapy designation for the treatment of patients with locally advanced or metastatic <FONT STYLE="white-space:nowrap">ALK-positive</FONT> <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) who have been previously treated with 2 or more ALK tyrosine kinase inhibitors and orphan drug designation for <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NVL-655</FONT> is currently being evaluated in the Phase 2 portion of the <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT>
Phase 1/2 clinical trial, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study of <FONT STYLE="white-space:nowrap">NVL-655</FONT> in patients with advanced
<FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC and other solid tumors (<U>NCT05384626</U>). The completed Phase 1 portion enrolled <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC patients who previously received at least one
ALK TKI and patients with other <FONT STYLE="white-space:nowrap">ALK-positive</FONT> solid tumors who had been previously treated with at least one prior systemic anticancer therapy. The primary objectives were to determine the recommended Phase 2
dose (RP2D) and if applicable, the maximum tolerated dose (MTD) of <FONT STYLE="white-space:nowrap">NVL-655</FONT> in patients with <FONT STYLE="white-space:nowrap">ALK-positive</FONT> solid tumors. Additional objectives included characterization of
the overall safety, tolerability, and pharmacokinetic profile, and evaluation of the preliminary anti-tumor activity of <FONT STYLE="white-space:nowrap">NVL-655.</FONT> The ongoing global, single arm, open label Phase 2 portion is designed with
registrational intent for TKI <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients with <FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC and to enable preliminary investigation for patients with
<FONT STYLE="white-space:nowrap">ALK-positive</FONT> NSCLC who are TKI na&iuml;ve. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Nuvalent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating <I>precisely</I> targeted therapies for patients with cancer,
designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome
resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, <FONT STYLE="white-space:nowrap">ALK-positive,</FONT> and
HER2-altered <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, and multiple discovery-stage research programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including, without limitation, implied and express statements regarding Nuvalent&#146;s strategy, business plans, and focus; the clinical development programs for zidesamtinib and <FONT STYLE="white-space:nowrap">NVL-655;</FONT> the
expected timing of reporting data readouts from Nuvalent&#146;s clinical trials of zidesamtinib and <FONT STYLE="white-space:nowrap">NVL-655;</FONT> the design and timing of the ALKAZAR trial, including alignment with the FDA regarding the design of
the trial; the potential clinical effects of zidesamtinib and <FONT STYLE="white-space:nowrap">NVL-655;</FONT> the potential of Nuvalent&#146;s pipeline programs, including zidesamtinib and <FONT STYLE="white-space:nowrap">NVL-655;</FONT> the
implications of data readouts and presentations; Nuvalent&#146;s research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words &#147;may,&#148; &#147;might,&#148;
&#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;aim,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;expect,&#148;
&#147;estimate,&#148; &#147;seek,&#148; &#147;predict,&#148; &#147;future,&#148; &#147;project,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;target&#148; or the negative of these terms and similar words or expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs
result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 7 OF 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g862522g0913031014890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Broadway, 14<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Cambridge, MA 02142</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Nuvalent.com</B></P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#146;s current expectations and
beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release,
including, without limitation: risks that Nuvalent may not fully enroll the <FONT STYLE="white-space:nowrap">ARROS-1,</FONT> <FONT STYLE="white-space:nowrap">ALKOVE-1</FONT> or ALKAZAR trials or that enrollment will take longer than expected;
unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies or clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical
trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of our product candidates; risks
that Nuvalent may not achieve the goals and milestones set forth in its OnTarget 2026 operating plan; the occurrence of adverse safety events; risks that the FDA, European Medicines Agency or other foreign regulators may not approve our potential
products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public
health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent&#146;s clinical trials, strategy, and future operations, including the <FONT STYLE="white-space:nowrap">ARROS-1,</FONT> <FONT
STYLE="white-space:nowrap">ALKOVE-1</FONT> and ALKAZAR trials; the timing and outcome of Nuvalent&#146;s planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent&#146;s intellectual
property. These and other risks and uncertainties are described in greater detail in the section entitled &#147;Risk Factors&#148; in Nuvalent&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period
ended June&nbsp;30, 2024, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent&#146;s views only as of today and should not be relied upon as
representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor
Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chelcie Lister </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nuvalent, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>clister@nuvalent.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amanda Sellers </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deerfield Group </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>amanda.sellers@deerfieldgroup.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PAGE 8 OF 8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nuvl-20240914.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/16/2024 10:26:25 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:nuvl="http://www.nuvalent.com/20240914"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.nuvalent.com/20240914"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nuvl-20240914_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nuvl-20240914_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nuvl-20240914_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/16/2024 10:26:26 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nuvl-20240914_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/16/2024 10:26:26 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="nuvl-20240914.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g862522g0913031014890.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g862522g0913031014890.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ -,# 2(  A$! Q$!_\0
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M2:F5-Q)HXJ%339EVBBBLSI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45069414510784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001861560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 14,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NUVALENT, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5112298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Nuvalent, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">One Broadway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">14th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">357-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Class&#160;A Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NUVL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "N,#!9E4P&Z7T$  #;$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V8;V^K-A3&OXK%IFF3VH)I_K5+(J5INT6WS<V:W'NE37OA@!.L F:V:9IO
MOV-((;LCA[Q),-@//Q\?GF,8[J1ZU1'GAKPG<:I'3F1,=NNZ.HAXPO25S'@*
M5S92)<Q 4VU=G2G.PF)0$KN^Y_7<A(G4&0^+<PLU'LK<Q"+E"T5TGB1,[>]X
M+'<CASH?)U[$-C+VA#L>9FS+E]Q\R18*6FZE$HJ$IUK(E"B^&3D3>GOG]^R
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MV%+)X/6"_.A=V7TWR9@B4%-S3C*8MXZ80OGK<N#C_KU2++1YN-PG:]F<A;@
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" "N,#!9EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "N,#!9!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( *XP,%G_QX&"[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *XP,%F97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MKC P695,!NE]!   VQ$  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *XP,%F?H!OPL0(  .(,   -
M          "  <$,  !X;"]S='EL97,N>&UL4$L! A0#%     @ KC P69>*
MNQS     $P(   L              ( !G0\  %]R96QS+RYR96QS4$L! A0#
M%     @ KC P61PX9>H_ 0  / (   \              ( !AA   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( *XP,%DD'INBK0   /@!   :
M      "  ?(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( *XP,%EED'F2&0$  ,\#   3              "  =<2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d862522d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d862522d8k.htm">d862522d8k.htm</File>
    <File>nuvl-20240914.xsd</File>
    <File>nuvl-20240914_lab.xml</File>
    <File>nuvl-20240914_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d862522d8k.htm": {
   "nsprefix": "nuvl",
   "nsuri": "http://www.nuvalent.com/20240914",
   "dts": {
    "inline": {
     "local": [
      "d862522d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "nuvl-20240914.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nuvl-20240914_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nuvl-20240914_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-14_to_2024-09-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d862522d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-14_to_2024-09-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d862522d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.nuvalent.com//20240914/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-24-219153-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-219153-xbrl.zip
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M*+(\N;QN%U= Y&4:H[P)5NR?/U'0#,@"%$"93IU0153(7(R4/,(#PB-%0)>
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M!*S:[4 $;PT^JF4(W*J''PL?R^6Y#0J+2R O2D%MI$RT/TFW??_AN.)\;"J
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M*KV6J,3@$KADP.YH), N8HG.W+$I41H9PQ9+$3*@Y$ZXG$5C;5V_,$_/\B9
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M@W5K0?FU,\BSQ1M@Y91_8F$.!!HRK'N"]- '1GP1]/6&'-S@8+VQ)L @]<R
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M<7Y5J2PR-X+ ,_*2Y R/#P0*$2<:40]8?X(E0CCKCA'(;88?2/DJDID#+NP
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M<$@"*]V<_QLN_M+]>G7Z_U!+ P04    " "N,#!9/WZ-GCX#  !-"P  $0
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MEJNDM^!68Q=PLUS[(Q^8;<>UMUW!NC%FFW/<WO3GO;EJ]@W]_ U02P,$%
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M'?A/86C8/Y=T!+TJ UR *H2+.[:!.MC-7"!BGMX.NA5W@C]2%C2\JUFE<0S
M5QG34?\L%@U]K:XC_K/[>A*=HAKN$#BQ4C<)#?P@CL,=CQ,_^ILNF]_BURL<
MPRCH3>D&82<2;0PTJHZ&(*L$LA3F;7MW-NH&P-B+Y5M@E4%!_"; [^:T]098
M7>-\_YC5VU_W=)# 3?^=5\HXG.+WN?/65\-F[4!4[TF/[N:<-7Q<M)_7$I"5
M!KC^N V8>BTD.%-Q2-6Q;IN[Z;<,:9.F[4#]4] D(6S,%XL5RV_'QZ:T5B2W
MA&R]%5X39 -OC2 2P7D%V"UA3;'#QLLH-^W>#N=['M& )I3-/LH5MZ!^9,JR
M+K,ED&M,\*H(&X2KU)#X?9*'0M\:7E<ME\EMU+<=MG>"J/D@$HOTC<#JPV'B
M]N'!?.%0I] 2Q@:F^*%(&ZP/J2+A+<M N0YDA2"M9 VZ:Q-EX%_H!!7]ZSA>
M$6$_ !J=XQB#:H/Z8=B+1QR)"FU7@Y&5<SH?CAS53DDC6Y;+&Q*LY'IJVQ],
M)S2)C.]Q[.>UM;2I,L#UQZV6-5HMK$5-+@Y2'5)Y^S6-DWYW5C0-FK8#=2)\
M]54+]]O%E!LOP9\EM82HOG6N.6@#IT8(B<Q<&3)I:RH=-%I&TK1;G.OFY2:8
M2[>DR6=Y]+DM7S^U1GAU#,9U=%\/^UI:5,#Y+(^[OK775,/F,9[O72Z(F,FI
M^4WP=3*7BY&ESQI^CKU"HM4G?/6V^,%0^V=\-;)(K.</QHI"D%6"O!32,SZ'
M-C0/^4R]E'?<R"WUC4/Y+II][X[<\S]02P,$%     @ KC P67=9PM?1!
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MO@!02P$"% ,4    " "N,#!9"?<::D$6  "H>0  #@              @ $
M    9#@V,C4R,F0X:RYH=&U02P$"% ,4    " "N,#!9[]T O&(H  #X"@$
M$0              @ %M%@  9#@V,C4R,F1E>#DY,2YH=&U02P$"% ,4
M" "N,#!9/WZ-GCX#  !-"P  $0              @ '^/@  ;G5V;"TR,#(T
M,#DQ-"YX<V102P$"% ,4    " "N,#!9FYF#P)D&  "Y20  %0
M    @ %K0@  ;G5V;"TR,#(T,#DQ-%]L86(N>&UL4$L! A0#%     @ KC P
M67=9PM?1!    RX  !4              ( !-TD  &YU=FPM,C R-# Y,31?
=<')E+GAM;%!+!08     !0 % $ !   [3@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d862522d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nuvl-20240914.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-14_to_2024-09-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2024-09-14</startDate>
            <endDate>2024-09-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-283">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-14_to_2024-09-14"
      id="Hidden_dei_EntityCentralIndexKey">0001861560</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-294">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-295">2024-09-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-296">NUVALENT, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-297">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-298">001-40671</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-299">81-5112298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-300">Nuvalent, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-301">One Broadway</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-302">14th Floor</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-303">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-304">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-305">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-306">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-307">357-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-308">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-309">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-310">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-311">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-312">Class&#160;A Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-313">NUVL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-314">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-14_to_2024-09-14" id="ixv-315">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
